Farooqi Ammad Ahmad, Fayyaz Sundas, Hou Ming-Feng, Li Kun-Tzu, Tang Jen-Yang, Chang Hsueh-Wei
Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore 54000, Pakistan.
Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Mar Drugs. 2014 Nov 13;12(11):5408-24. doi: 10.3390/md12115408.
It is becoming more understandable that an existing challenge for translational research is the development of pharmaceuticals that appropriately target reactive oxygen species (ROS)-mediated molecular networks in cancer cells. In line with this approach, there is an overwhelmingly increasing list of many non-marine drugs and marine drugs reported to be involved in inhibiting and suppressing cancer progression through ROS-mediated cell death. In this review, we describe the strategy of oxidative stress-based therapy and connect the ROS modulating effect to the regulation of apoptosis and autophagy. Finally, we focus on exploring the function and mechanism of cancer therapy by the autophagy modulators including inhibitors and inducers from non-marine drugs and marine drugs.
越来越容易理解的是,转化研究目前面临的一个挑战是开发能够适当靶向癌细胞中活性氧(ROS)介导的分子网络的药物。按照这种方法,据报道,越来越多的非海洋药物和海洋药物通过ROS介导的细胞死亡来抑制癌症进展。在这篇综述中,我们描述了基于氧化应激的治疗策略,并将ROS调节作用与细胞凋亡和自噬的调节联系起来。最后,我们重点探讨包括非海洋药物和海洋药物中的抑制剂和诱导剂在内的自噬调节剂在癌症治疗中的功能和机制。